Trial Profile
Prostaglandin Inhibition and Programmed Cell Death Protein 1 (PD-1)/Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA4) Blockade in Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Aspirin; Ipilimumab
- Indications Malignant melanoma
- Focus Therapeutic Use
- 19 Sep 2022 Status changed from active, no longer recruiting to completed.
- 25 Aug 2020 Planned number of patients changed from 43 to 27.
- 25 Aug 2020 Planned End Date changed from 7 Jun 2023 to 30 Jun 2024.